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Abstract 1 
Well over a hundred types of naturally occurring covalent modifications can be made to 2 
ribonucleotides in RNA molecules. Moreover, several types of such modifications are each 3 
known to be catalysed by multiple enzymes which largely appear to modify distinct sites 4 
within the cellular RNA. In order to aid functional investigations of such multi-enzyme RNA 5 
modification types in particular, it is important to determine which enzyme is responsible 6 
for catalysing modification at each site. Two methods, Aza-IP and methylation-iCLIP, were 7 
developed and used to map genome-wide locations of methyl-5-cytosine (m5C) RNA 8 
modifications inherently in an enzyme specific context. Though the methods are quite 9 
distinct, both rely on capturing catalytic intermediates of RNA m5C methyltransferases in a 10 
state where the cytosine undergoing methylation is covalently crosslinked to the enzyme. 11 
More recently the fundamental methylation-iCLIP principle has also been applied to map 12 
methyl-2-adenosine sites catalysed by the E.Coli RlmN methylsynthase. Here I describe the 13 
ideas on which the two basic methods hinge, and summarise what has been achieved by 14 
them thus far. I also discuss whether and how such principles may be further exploited for 15 
profiling of other RNA modification types, such as methyl-5-uridine and pseudouridine. 16 
 17 
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Introduction 1 
The canonical nucleotides in RNA molecules can undergo various types of stable biochemical 2 
modification, including but not limited to methylation (Machnicka et al. 2013; Boccaletto et 3 
al. 2018). The majority of known modification types have been identified in all three 4 
kingdoms of life and are thought to be of significant biological importance (Towns and 5 
Begley 2012). Of the 100+ types of RNA modifications, some of their genomic co-ordinates 6 
have been determined precisely though not always comprehensively; nonetheless a core 7 
view of their distribution is already apparent (Grosjean 2015). Transfer RNAs (tRNAs) are the 8 
most heavily modified RNA biotype with different types of modifications occurring every 9 
few nucleotides; stability, amino-acylation, and translation fidelity are just a few of the 10 
crucial functions that are directly attributable to some individual tRNA modifications (El 11 
Yacoubi et al. 2012). Modifications on ribosomal RNAs (rRNAs) which influence their stability 12 
(Sharma and La Fontaine 2015), as well as modifications occurring on messenger RNAs 13 
(mRNAs) which can influence turnover or rates of translation (Zhao et al. 2017), are also 14 
some notable examples of key functional roles already demonstrated.  15 
Much of our knowledge relating to the enzymatic factors that catalyse some of these RNA 16 
ribonucleotide modifications originates from studies performed in prokaryotes, archaea and 17 
single-celled eukaryotes (Grosjean and Benne 1998). A common theme that clearly emerged 18 
even from such early investigations is that a single modification type is very often catalysed 19 
by multiple enzymes, and further that such enzymes will only act on specific sites in the 20 
cellular RNA (Ferre-D’Amare 2003). Perhaps two of the most notable examples of such 21 
modification types are methyl-5-cytosine (m5C) and pseudouridine. Indeed in mammals, 22 
m5C in cellular RNA is catalysed by at least eight enzymes (NSun1-7, Dnmt2), and the target 23 
RNA sites for a few of these have been surveyed in a genome-wide context. The previously 24 
incorrectly suspected DNA methyltransferase, Dnmt2, has been found to methylate 25 
cytosines at position 38 of a few tRNA isoacceptors (Schaefer et al. 2010; Khoddami and 26 
Cairns 2013). NSun2 on the other hand methylates cytosines predominantly located at 27 
positions 48-50 in tRNAs (Khoddami and Cairns 2013; Hussain et al. 2013a), and also 28 
appears to be capable of methylating a few sites in other ncRNAs as well as potentially in 29 
mRNAs (Squires et al. 2012; Khoddami and Cairns 2013; Hussain et al. 2013a; Hussain et al. 30 
2013b). NSun3 catalyses methylation at position C34 of mitochondrial tRNAs (van Haute et 31 
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al. 2016) whereas NSun6 methylates C72 of a few cytoplasmic tRNA isoacceptors (Haag et 1 
al. 2016). Using an NSun4 knockout transgenic mouse control coupled with a bisulfite 2 
sequencing approach, it was also demonstrated that the NSun4 enzyme catalyses 3 
methylation of C911 of mouse 12S rRNA (Metodiev et al. 2014). The target sites of a few of 4 
the 13 known mammalian pseudouridine synthases have been profiled, and such sites are 5 
also found to be just as enzyme-specific (Li et al. 2015; Safra et al. 2017; Zaganelli et al. 6 
2017).   7 
Whereas the enzyme specificities of some pseudouridine sites have so far been determined 8 
by performing genetic perturbations, those for RNA m5C sites have instead been established 9 
largely using substrate-trapping techniques. The two current methods which enabled this 10 
are 5-azacytidine-mediated IP (Aza-IP) (Khoddami and Cairns 2013) and methylation-iCLIP 11 
(miCLIP) (Hussain et al. 2013a). Though distinct, both techniques work by stalling the normal 12 
catalytic process at a step where a key residue in the enzymatic active site becomes 13 
covalently crosslinked to the cytosine undergoing modification. The enzyme-substrate 14 
catalytic intermediate complexes are purified, and the precise crosslink/modification sites 15 
then determined using next generation sequencing-computational approaches.  16 
Further to helping understand how the Aza-IP and miCLIP techniques work mechanistically, 17 
an appreciation of the relevant catalytic mechanism will also help establish the potential 18 
scope of the method principle i.e. its suitable application to other modification types. Here I 19 
thus begin with a brief historical perspective of our knowledge pertaining to enzyme-RNA 20 
catalytic adducts. I then describe how the Aza-IP and miCLIP techniques allow nucleotide-21 
resolution determination of RNA m5C sites in a genome-wide context, and what they have 22 
helped uncover so far. Finally I propose in more detail how the method principle may be 23 
applied to other RNA modification types and particular enzymes.  24 
 25 
Capturing catalytic crosslinks in ribonucleotide modification reactions 26 
Several early studies had implicated the formation of a covalently linked complex between 27 
various types of pyrimidine modifying enzymes and either target pyrimidines existing in 28 
monomeric form or within RNAs (Yeh et al. 1967; Schoemaker and Schimmel 1977a; 29 
Schoemaker and Schimmel 1977b; Kunitani and Santi 1980; Santi and Hardy 1987). Such 30 
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complexes, referred to by biochemists as a type of Michael adduct (Box 1), were established 1 
as representing catalytic intermediates which in a later step of the pathway are resolved to 2 
release the fully modified pyrimidine and regenerate the active enzyme. An important 3 
example were aminoacylation reactions catalysed by tRNA synthetases, which were shown 4 
to proceed via a Michael adduct forming on a universally conserved uridine at position 8 of 5 
tRNAs (Schoemaker and Schimmel 1977a; Schoemaker and Schimmel 1977b; Starzyck et al. 6 
1982). It was further demonstrated that a key cysteine residue in the synthetase enzyme 7 
likely performs a nucleophilic attack on the 6-carbon of the uracil heterocyclic ring to form 8 
the covalent crosslink (Starzyck et al. 1982).  9 
Nucleophilic attack mediated by a cysteine residue from within the enzymatic active site 10 
indeed appears to be an established common feature of Michael adduct formation in RNA 11 
ribonucleotide modification reactions (Kealey and Santi 1991), including those mediated by 12 
RNA m5C methyltransferase enzymes (Liu and Santi 2000). According to the established 13 
enzymatic scheme, covalent bond formation between the key cysteine residue in RNA m5C 14 
methyltransferases and the 6-carbon of the cytosine heterocyclic ring renders the 15 
neighbouring 5-carbon susceptible to electrophilic attack. A methyl group can then be 16 
readily transferred to the 5-carbon before abstraction of its hydrogen. Elimination of the 17 
enzyme from the 6-carbon is the final step of the scheme (Figure 1A). It was proposed (Santi 18 
et al. 1983), and later demonstrated (Wu and Santi 1985), that presence of a nitrogen atom 19 
in place of the carbon at position 5 of the base ring i.e. as occurs in 5-azacytosine, would 20 
stall the enzymatic process. In such a scenario, although normal enzyme-substrate 21 
crosslinking occurs, the subsequent step of methyl group addition to position 5 cannot occur 22 
thus yielding a stabilised Michael adduct (Figure 1B). Presence of 5-azacytosine in place of 23 
cytosine in RNA would thus represent a potential mechanism for capturing crosslinked m5C 24 
methyltransferase-cytosine substrate complexes. The Aza-IP method is centred on this 25 
principle. 26 
An unexpected finding further made during the aforementioned investigations of the 27 
relevant enzymatic mechanism, was that although DNA m5C methyltransferases and RNA 28 
m5C methyltransferases share common catalytic motifs, they are observed to employ 29 
distinct conserved cysteine residues as the nucleophilic catalyst (Liu and Santi 2000). 30 
Particularly puzzling was the fact that the pivotal cysteine residue used by DNA m5C 31 
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methyltransferases as the nucleophile was found to be just as highly conserved in RNA 1 
methyltransferases but apparently not required for methyl group addition to RNA 2 
substrates. It was later shown that this second cysteine residue in RNA methyltransferases is 3 
indeed also involved in the catalytic process, but in fact at a step following the methyl group 4 
addition (King and Redman 2002; Redman 2006), making it likely that it acts as the general 5 
base required for abstraction of the hydrogen from the methylated 5-carbon (Lee et al. 6 
2005). Thus substitution of this cysteine could prevent hydrogen abstraction and also the 7 
subsequent elimination of the enzyme from the methylated substrate (Figure 1C), thereby 8 
offering a means of capturing the Michael adducts in these reactions. The miCLIP method is 9 
based on such principles.  10 
 11 
Aza-IP and miCLIP for genome wide profiling of RNA ribonucleotide modifications 12 
5-azacytidine mediated RNA immunoprecipitation (Aza-IP) 13 
The Aza-IP technique was developed and initially used for genome wide profiling of RNA 14 
m5C modifications catalysed by human NSun2 and Dnmt2 (Khoddami and Cairns 2013). Full 15 
protocol details and relevant technical commentaries have been published elsewhere 16 
(Khoddami and Cairns 2014). Briefly, the methodology involved culturing cells in the 17 
presence of 5-azacytosine in order to enable incorporation of the nucleotide analogue into 18 
RNAs during their transcription. Ectopic expression of epitope-tagged Dnmt2 or NSun2 19 
enzyme was performed, and antibodies complementary to the epitope tag were then used 20 
to purify the enzyme-RNA Michael adducts. Early in the library preparation, these 21 
complexes then dissociate in solution resulting in a 5-azacytosine ring in an open 22 
conformation which will base pair not with guanosine but instead with cytosine (Jackson-23 
Grusby et al. 1997); thus in synthesized cDNAs, G to C substitutions are expected at enzyme-24 
targeted sites. PCR-amplified libraries are prepared and then run on a high-throughput 25 
Illumina sequencer. Finally, computational algorithms are used to determine positions of G 26 
to C substitutions compared to reference sequence, thus enabling RNA m5C modification 27 
sites to be inferred precisely at nucleotide-resolution.                 28 
Cytosine 38 of a few tRNA isoacceptors were previously characterised as target sites for the 29 
Dnmt2 m5C methyltransferase (Schaefer et al. 2010), and such findings were recapitulated 30 
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in the Aza-IP study. The previously known targets of NSun2 was limited to only a few tRNA 1 
isoacceptors, with positions 48, 49, and 50 most frequently identified as the target sites. The 2 
Aza-IP study not only confirmed all previously known such sites, but also showed that 3 
several more tRNA isoacceptors were in fact methylated at the 48-50 positions. The 4 
enrichment-based genome-wide approach had therefore succeeded in yielding a 5 
significantly more comprehensive map of NSun2-target m5C sites in tRNAs. The study also 6 
unveiled a few novel m5C sites located in other RNA biotypes including in 5S rRNA, Vault 7 
RNAs, SCARNA2, Y RNA and 7SL RNA. Although several potential NSun2-depedent target 8 
sites in mRNAs were also identified by Aza-IP, only one of these (located in the SHF mRNA) 9 
passed the rigorous statistical criteria that was applied to accurately call targeted tRNA sites 10 
too.  11 
 12 
Methylation-individual nucleotide resolution crosslinking immunoprecipitation (miCLIP) 13 
The miCLIP method was developed and also initially used to map the genome wide locations 14 
of NSun2 in RNAs (Hussain et al. 2013a). Full protocol details along with relevant notes and 15 
discussion have been published elsewhere (George et al. 2017). Briefly, the approach 16 
involved ectopic expression of an epitope-tagged point-mutant form of NSun2. Here the 17 
catalytic cysteine thought to act as the general base, and thus critical for allowing release of 18 
the enzyme from the methylated substrate, was mutated to alanine. The stabilised Michael 19 
adducts were then purified using an antibody complementary to the epitope tag. In this 20 
methodology, the crosslink which forms on natural target cytosines are more permanently 21 
stable, and can be subjected to denaturing polyacrylamide gel electrophoresis thus enabling 22 
purification of enzyme-substrate complexes at exceptionally high stringency. Reverse 23 
transcriptions of isolated substrate RNAs stall at the Michael adduct crosslink sites, and thus 24 
the final nucleotide of the synthesized cDNAs are predicted to correspond to the 25 
methylated cytosine position. The use of unique molecular identifiers (UMIs) within the 26 
primers used for RT during library preparation allow for PCR duplicate reads to be discarded, 27 
thus enabling mapping of the high-throughput sequence reads at the cDNA-level.  28 
The NSun2 miCLIP study mirrored the major findings of Aza-IP, in that opposed to just a 29 
small handful, most human tRNA isoacceptors were in fact found m5C modified at the 30 
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48/49/50 positions. Further, the novel NSun2-dependent m5C sites in the Vault ncRNAs and 1 
5S rRNA reported by the Aza-IP study were also detected by miCLIP. The miCLIP study also 2 
reported several NSun2-dependent mRNA target sites (Hussain et al. 2013a; Hussain et al. 3 
2013b), including the SHF mRNA site which reached the statistical cut-off applied in the Aza-4 
IP study, though these remain to be cross-validated using additional methods. Some of the 5 
NSun2 miCLIP-detected sites in ncRNAs were however additionally validated and further 6 
investigated in the study. For example, mutations in the human NSun2 gene had previously 7 
been established as causative in Mendelian intellectual disability syndromes in some 8 
families (Abbasi-Moheb et al. 2012; Khan et al. 2012); bisulfite sequencing of RNA derived 9 
from dermal fibroblasts of unaffected siblings were used to confirm the presence of miCLIP-10 
detected m5C sites in Vault RNAs, whereas these methylations were found to be absent in 11 
bisulfite-sequenced Vault RNA derived from affected patient cells (Hussain et al. 2013a). 12 
 13 
Subsequent further successful applications of Aza-IP and miCLIP  14 
Aza-IP has more recently been applied to determine the genome-wide profile of NSun6 m5C 15 
target sites (Haag et al. 2015), and it was demonstrated that NSun6 targets position 72 of 16 
cysteine and threonine tRNA isoacceptors in a manner dependent on the presence of their 17 
CCA tails. miCLIP has further been applied to determine the targets of the NSun3 RNA 18 
methyltransferase, and it was found that the enzyme targets position 34 of mitochondrial 19 
methionine tRNA (Van Haute et al 2016). The study also demonstrated that NSun3 20 
mutations are causative in an autosomal recessive form of mitochondrial disease 21 
characterised by developmental disability and oxidative phosphorylation deficiency in 22 
skeletal muscle. Mitochondria of patient-derived dermal fibroblasts were found to have 23 
markedly decreased levels of protein synthesis rates compared to that within mitochondria 24 
from matched control cells. Since the miCLIP-detected m5C site at C34 of mitochondrial 25 
methionine tRNA was previously reported to be a site carrying the 5-formylcytosine (f5C) 26 
modification, it was further hypothesized that m5C at this site might represent an 27 
intermediate which is further metabolised to form a final f5C at this position. Consistent 28 
with this idea, it was indeed found that the NSun3-defecient dermal fibroblasts lacked f5C at 29 
the mitochondrial methionine tRNA C34 site, whereas it was readily detected at this 30 
position in matched controls. In summary, the NSun3 study identified the presence of m5C 31 
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at the C34 ‘wobble’ position of mitochondrial translation initiator tRNA, which was shown to 1 
be necessary for formation of f5C at this position, and likely thus for efficient mitochondrial 2 
protein synthesis. Disruption of the NSun3 enzyme, which catalyses the initial step of the 3 
modification scheme, results in a characteristic mitochondrial disease phenotype in humans.  4 
Much more recently, the methylation-iCLIP catalytic crosslinking principle was applied to 5 
map methyl-2-adenosine (m2A) modifications catalysed by the E.Coli RNA methylsynthase, 6 
RlmN (Stojkovic et al. 2018). The method termed miCLIP-MaPseq mainly differs from the 7 
original miCLIP technique in that it employs the thermostable group II reverse transcriptase 8 
(TGIRT) for synthesis of cDNAs during library preparation. As TGIRT has a high tendency to 9 
read through crosslink sites, cDNA truncations are not observed, but instead mutations 10 
specifically at the crosslink site are frequently inserted in the cDNAs during synthesis. This 11 
then enables precise target sites in RNAs to be identified via mutation screening within the 12 
mapped cDNA libraries. The study successfully mapped RlmN target sites in 23S rRNA as well 13 
as showing that the enzyme can methylate several tRNA isoacceptors. 14 
 15 
Shortcomings and scope for improvement of the two techniques 16 
Though both miCLIP and Aza-IP have unveiled several novel RNA m5C sites, some of which 17 
have further been demonstrated to be have significant biological significance, both 18 
techniques suffer from shortcomings.  19 
For Aza-IP, perhaps the main one, is that 5-azacytosine is also incorporated into DNA during 20 
replication and inhibits DNA methylation via covalent trapping of DNA methyltransferases. 21 
When the aim of an investigation becomes determining the biological roles of m5C RNA 22 
modifications, due consideration must therefore be given to the impact that the unwanted 23 
DNA methylation inhibition might have on the biological phenomena being studied. This 24 
may be particularly important when studying biological processes known to hinge on 25 
epigenetic changes such as early developmental or cancer disease states for example. A 26 
much more minor shortcoming of the Aza-IP approach is that it may not be relatively 27 
effective in detecting low-abundance modifications. This is since 5-azacytosine will compete 28 
with cytosine for incorporation into RNA during transcription: thus for each reference 29 
cytosine site, some transcripts will contain 5-azacytosine, but others which might be some 30 
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significant proportion, will contain cytosine. Thus a methylation attempt would need to be 1 
made specifically on the transcripts containing 5-azacytosine at the correct position for 2 
crosslinking to occur. For RNAs methylated at high stoichiometry this is not an issue, but low 3 
abundance modifications, such as those that might occur on mRNAs for example, may fall 4 
below the limits of detection.  5 
For miCLIP, the main disadvantage is the need to ectopically express the relevant cysteine 6 
point mutant form of the enzyme, which could potentially lead to the detection of non-7 
physiological off-targets. The ideal m5C-profiling catalytic crosslinking experiment, perhaps, 8 
would be a miCLIP approach where the relevant cysteine mutation is knocked into the RNA 9 
methyltransferase gene via editing. As alluded to earlier, catalytic crosslinking has the likely 10 
potential to be used to profile some various types of RNA ribonucleotide modifications; an 11 
Aza-IP-type approach applied to detect uridine modifications (discussed in further detail in 12 
the following section) would also be particularly attractive, as there is no longer the concern 13 
of DNA methylation inhibition.  14 
In summary, though the Aza-IP and miCLIP techniques can detect RNA modification sites 15 
with a very good degree of confidence, when used in their current form, a few important 16 
caveats as summarised above should be considered. 17 
 18 
Applying catalytic crosslinking principles to profile other RNA modifications 19 
Considering especially the recent successful application of the fundamental methylation-20 
iCLIP catalytic crosslinking principle to map an adenosine modification (Stojkovic et al. 21 
2018), it is conceivable that substrate trapping could indeed be employed to map a variety 22 
of other RNA modification types. As discussed previously, key to nucleotide modification 23 
catalytic crosslinking is the existence of a central amino acid residue which forms a covalent 24 
bond with the target substrate; in some cases a second key catalytic residue is critical for 25 
resolution of the covalent complex, but in other cases, such as for DNA methyltransferases 26 
for example, no such second critical residue can be distinguished. Thus when deciding 27 
whether Aza-IP- or miCLIP-type experiments might be suitable for mapping a particular RNA 28 
modification type, a couple of broad guidelines may be posited: i) modifications identified to 29 
involve two key residues for catalysis, one for covalent bond formation and the other for 30 
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resolving the covalent intermediate, may be amenable to both an Aza-IP- and miCLIP-type 1 
approach; ii) modifications thought to involve one key catalytic residue i.e. for covalent 2 
bond formation, may be amenable only to a potential Aza-IP-type methodology. To provide 3 
a more detailed illustration, below I work through a couple of examples of uridine 4 
modifications which may be amenable to catalytic crosslinking-based mapping.  5 
 6 
Methyl-5-uridine (m5U) 7 
A good candidate for catalytic crosslinking-based profiling is perhaps methyl-5-uridine 8 
(m5U): like m5C, a pyrimidine modification which involves methylation at the 5-carbon 9 
position of the base ring. In support of this, it has previously been shown that bacterial tRNA 10 
m5U methyltransferase proceeds via a catalytic mechanism similar to that described for 11 
m5C methyltransferases (Santi and Hardy et al. 1987; Kealey et al. 1994), thus being 12 
dependent on a catalytic cysteine nucleophile for Michael adduct formation (Kealey and 13 
Santi 1991). During such studies it was found that presence of the uridine analogue 5-14 
flourouracil (5FU), where the hydrogen at the 5-carbon is substituted with a fluorine atom, 15 
in RNAs results in covalent trapping of m5U methyltransferases. In such cases, the catalytic 16 
process proceeds to include methylation of the 5-carbon, however because of the stability 17 
of the carbon-fluorine bond, the enzymatic scheme stalls yielding a stabilised Michael 18 
adduct (Figure 2). The use of 5FU, which is readily incorporated into cellular RNA during 19 
transcription, may thus enable m5U profiling i.e. akin to the use of 5-azacytosine to profile 20 
m5C positions in cellular RNA.  21 
It has also been shown that the m5U methyltransferases behave like most RNA m5C 22 
methyltransferases, thus requiring a second key catalytic residue to resolve the catalytic 23 
adducts and complete the enzymatic process (Lee et al. 2005; Alian et al. 2008). However, 24 
unlike the case with RNA m5C methyltransferases, the second central catalytic residue in 25 
m5U methyltransferases was in fact found to be a glutamate, not a cysteine. It was shown 26 
that the catalytic glutamate likely acts as the general base required for abstraction of the 27 
hydrogen from the already methylated 5-carbon (Lee et al. 2005). Thus, an inhibition of this 28 
penultimate step would in turn result in prevention of the final step, i.e. elimination of the 29 
enzyme from 6-carbon of the substrate uridine. It follows that mutation of this conserved 30 
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catalytic glutamate residue may potentially enable a relevant miCLIP-type experiment to be 1 
performed.   2 
Bacteria and yeast harbour a single known m5U methyltransferase enzyme, TrmA and Trm2 3 
respectively. These are known to universally target position U54 of the T-loop in tRNAs. In 4 
mammals, two m5U methyltransferases TRMT2A and TRMT2B, are predicted based on 5 
sequence homology. Experimentally determined target sites for either enzyme are however 6 
yet to be reported. It is noteworthy that, apart from a few of the key residues, there is only 7 
very moderate sequence homology within the catalytic domains of the two enzymes; they 8 
likely thus potentially target distinct sites in the cellular RNA. Aza-IP-type and/or miCLIP-9 
based experiments may be informative here. 10 
 11 
Pseudouridine 12 
The isomerisation of uridine to pseudouridine is known to be catalysed by families of 13 
pseudouridine synathases in the three kingdoms of life. These can be grouped according to 14 
phylogenetic association with the five bacterial enzymes, TruA, TruB, TruD, RluA and RsuA, 15 
which modify distinct sites mostly found in tRNAs, rRNAs and snRNAs. Similar to the 16 
observations with m5U methyltransferases, some bacterial pseudouridine synthases have 17 
also been found to form stable complexes when incubated with tRNA substrates containing 18 
5FU in place of uridine ribonucleotides (Huang et al. 1998; Gu et al. 1999). However, unlike 19 
RNA m5C and m5U methyltransferases, pseudouridine synthases utilise an aspartate 20 
residue, as opposed to a cysteine residue, to form a covalent attachment to the uridine. The 21 
precise chemical process via which the covalent attachment occurs and its exact place in the 22 
enzymatic scheme, is however as of yet, not fully clear (Spedaliere et al. 2004). To add to 23 
the uncertainty, details of the catalytic mechanism employed may potentially differ for 24 
pseudouridine synthases belonging to different phylogenetic families (Hamma and Ferre-25 
D’Amare 2006). Nonetheless, there is some evidence which suggests that at least two 26 
distinct bacterial pseudouridine synthases, TruA and RluA, do most likely catalyse their 27 
reactions via covalent attachment to the uridine substrate and that the crosslinks can 28 
indeed be stabilised via substitution with 5FU in targets (Huang et al. 1998; Gu et al. 1999; 29 
Spedaliere and Mueller 2004). 30 
13 
 
 1 
Of the 13 known mammalian pseudouridine synthases, the target sites of only a few have 2 
been profiled in a genome or transcriptome-wide context. These include the TruA family 3 
member PUS1, TruB members TRUB1 and TRUB2, and the TruD family member PUS7 (Li et 4 
al. 2015; Safra et al. 2017). These studies, which relied on genetic perturbation of the 5 
respective enzymes via gene disruption or siRNA-mediated knockdown, indicated that 6 
TRUB1, PUS7 and PUS1 can all catalyse uridine isomerisation at specific sites in human 7 
mRNAs. Additionally, two novel PUS1-dependent pseudouridine sites in the SRA lncRNA 8 
were also identified. A protein-RNA interaction based genome-wide screen for the 9 
RsuA/RluA member RPUSD4 has also been performed via the HITS-CLIP strategy, and aided 10 
in revealing that the enzyme targets mitochondrial tRNAs (Zaganelli et al. 2017). 11 
Collectively, such findings indicate that all mammalian pseudouridine synthases might act 12 
on distinct sites within the cellular RNA as opposed to having redundant enzymatic roles. 13 
Thus enzyme-specific genome-wide profiling of pseudouridine modification in mammalian 14 
systems will likely help uncover new important insights into its wider functional roles. Based 15 
on current observations, the RluA/RsuA members RPUSD1-4 and the TruA members PUS1, 16 
PUSL1, and PUS3 may be considered prime candidates for attempts at an Aza-IP-type 17 
pseudouridine profiling method, where 5FU is employed for catalytic crosslinking 18 
stabilisation.  19 
 20 
Concluding remarks 21 
Though enzyme-specified profiling of RNA ribonucleotide modifications can currently 22 
involve genetic perturbation, to perform such experiments reliably requires gene disruption 23 
which is labour intensive. Such an approach also relies on comparing two conditions i.e. wt 24 
vs ko, meaning that identified sites are much more susceptible to the details of the 25 
computational analysis workflow/statistical models employed to call differential expression. 26 
Though Aza-IP- and miCLIP-type profiling currently have their shortcomings too, the ability 27 
to profile specific enzymatic targets inherently may be considered overall a distinct 28 
advantage. Given the current pervasive observations of unique site-specificity of RNA 29 
modification enzymes, further improvement and developments of the two techniques will 30 
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likely render them as ideally placed to more informatively profile some types of RNA 1 
ribonucleotide modification in future.  2 
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Box 1. The Michael addition reaction and Michael adducts 8 
Initially described by Arthur Michael in 1887, in the simplest of terms, the Michael reaction 9 
can be viewed as a widely occurring atom-economical method of carbon-carbon bond 10 
formation (Michael 1887). More recent definitions heed recognition that common to any 11 
Michael reaction is the addition of a nucleophile to an unsaturated carbonyl compound. 12 
Accordingly, the mechanism is also found to be widely adopted in natural reactions for the 13 
formation of asymmetrical carbon bonds, including carbon-nitrogen, carbon-oxygen, and 14 
carbon-sulphur. Thus although the nucleophile is commonly a carbanion, it may also be, for 15 
example, the sulphur-containing group of a cysteine amino acid residue. In some enzymatic 16 
reactions, the nucleophilic sulfhydryl group of a cysteine residue within the enzymatic active 17 
site can therefore participate directly in a Michael reaction, and form a bond via its sulphur 18 
with a suitable carbon in the target. As an example, within the heterocyclic ring of 19 
pyrimidine base groups, the 6-carbon is particularly susceptible to nucleophilic addition, and 20 
thus in some pyrimidine modification reactions, cysteine sulphur:base ring 6-carbon Michael 21 
addition reactions can be observed. In such examples however, the carbon-sulphur bond is 22 
only an intermediate in the full enzymatic reaction, and is thus eventually broken. The 23 
intermediate conjugate in these and similar cases has often been referred to as a ‘Michael 24 
adduct’ (Starzyk et al. 1982; Santi and Hardy 1987). 25 
 26 
Figure legends 27 
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Figure 1. Enzyme-substrate covalent intermediates in RNA m5C modification reactions, 1 
and their capture.  (A) The heterocyclic ring of the base group of a cystosine ribonucleotide 2 
is shown. For the sake of clarity, less relevant details of the chemical structure (positions of 3 
nitrogen atoms within the ring etc.) have been omitted. RNA m5C methyltransferase 4 
enzymes are known to harbour a catalytic cysteine residue capable of mediating a 5 
nucleophilic attack (:Enz) of the carbon at the 6 position of the ring. This enables a covalent 6 
bond to form between the catalytic cysteine of the enzyme and the 6-carbon, which in turn 7 
renders the 5-carbon of the ring susceptible to electrophilic attack. A one carbon group, 8 
+CH3, (provided by an S-Adenosyl Methionine donor; not shown here) can then form a 9 
covalent linkage with the 5-carbon. The proton from the 5-carbon is then abstracted in likely 10 
an enzyme dependent manner, and finally, β-elimination from the methylated 11 
ribonucleotide regenerates the free active enzyme. (B) In 5-azacytosine, position 5 of the 12 
ring harbours a nitrogen instead of the usual carbon. Although covalent linkage of the 13 
enzyme to the 6-carbon occurs as normal, the methyl group does not readily attack the 5-14 
nitrogen. The catalytic reaction thus stalls prior to the methylation. (C) In the normal 15 
reaction, a second catalytic cysteine residue likely acts as the general base required for 16 
proton abstraction from the 5-carbon following its methylation. A mutated form of the 17 
enzyme where this key cysteine has been substituted, :Enz-CBM (enzyme-catalytic base 18 
mutant), is still able to form the normal covalent linkage to the cytosine. However, the 19 
enzymatic scheme stalls at the proton abstraction step, meaning that β-elimination of the 20 
enzyme from the methylated ribonucleotide does not occur either.  21 
 22 
Figure 2. The use of 5-flurouracil to capture enzyme-substrate covalent intermediates in 23 
RNA m5U modification reactions. In 5-flurouracil, there is a fluorine in place of the usual 24 
hydrogen attached to the 5-carbon of the heterocyclic ring of the base. An m5U 25 
methyltransferase successfully forms a covalent bond with the 6-carbon during the catalytic 26 
reaction. This renders the 5-carbon susceptible to electrophilic attack, and a methyl group is 27 
transferred to it. However, due to the particularly stable nature of the 5-carbon:fluorine 28 
bond, fluorine abstraction does not occur. The enzymatic scheme therefore stalls, and the 29 
m5U methyltransferase remains covalently bound to its substrate ribonucleotide.   30 
 31 
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